Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Underwent curative hepatectomy;~* Diagnosis of HCC was confirmed by postoperative histopathology;~* Liver function Child-Pugh A or B;~* Performance status score 0 or 1~* With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion; Receive immune checkpoint inhibitors based adjuvant therapy.~Exclusion Criteria:~* Receive neoadjuvant immune checkpoint inhibitors therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Immune checkpoint inhibitors based adjuvant therapy (Type: None): Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
- Without adjuvant therapy (Type: None): Patients in this arm will not receive any adjuvant therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).